Buy Rating Affirmed on Masimo Amid Board Restructuring and Growth Prospects
In a report released on September 20, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price ...
bovnews3d
Jefferies Issues Underperform Rating for Senseonics Holdings Inc (SENS) Stock
Senseonics Holdings Inc (SENS) stock saw a decline, ending the day at $0.41 which represents a decrease of $-0.03 or -6.82% from the prior close of $0.44. The stock opened at $0.49 and touched a low ...
Continuous Glucose Monitoring (CGM) Systems Market Size (USD 31.70 Billion By 2031): Growth Prospects & Innovations
Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...
Alert: Fed Rate Cut Decision Day
After more than a year of expected monetary policy easing, this afternoon is decision day. The Federal Reserve will issue its FOMC statement at 2:00 p.m. today. The media teased markets with the idea ...
Senseonics and Ascensia announce FDA approval for one-year CGM system
Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.
bovnews5d
Why Did Senseonics Holdings Inc (SENS) Stock See 0.82% Surge in the Last 90 Days?
Senseonics Holdings Inc (SENS) stock saw a decline, ending the day at $0.39 which represents a decrease of $-0.02 or -4.88% from the prior close of $0.41. The stock opened at $0.41 and touched a low ...
drugdeliverybusiness5d
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.
BioWorld5d
FDA clears Senseonic’s Eversense one-year implantable CGM
The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...
Becker's Hospital Review5d
Glucose monitor receives FDA clearance
The FDA has cleared Senseonics and Ascensia Diabetes Care's Eversense 365 Glucose Monitoring System. This system is designed for Type 1 and Type 2 diabetics 18 and older and will be the first ...
Monthly Prescribing Reference5d
Long-Term CGM System Eversense 365 Gets FDA Clearance
Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...
Senseonics Holdings, Inc.: Eversense 365 Receives FDA Clearance: The World's First One Year CGM
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...
FierceBiotech5d
FDA clears Senseonics' 365-day Eversense CGM implant
After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...